March 08, 2013 at 08:00 AM EST
New Partnerships & Brand Loyalty - Research Report on Acura Pharmaceuticals, Élan Corp, Hospira, Alkermes and Valeant

NEW YORK, March 8, 2013 /PRNewswire/ --

Today, Investors Alliance announced new research reports highlighting Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), Élan Corporation, Plc (NYSE: ELN), Hospira, Inc. (NYSE: HSP), Alkermes Plc. (NASDAQ: ALKS) and Valeant Pharmaceuticals Intl Inc. (NYSE: VRX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Acura Pharmaceuticals, Inc. Research Report

Acura Pharmaceuticals enters the chain drug store market via its new next generation pseudoephedrine with abuse deterrent technology. Nexafed[pseudoephedrine hydrochloride (HCI)] - a 30 mg immediate-release pseudoephedrine product that combines effective nasal-congestion relief with a unique technology that disrupts the conversion of pseudoephedrine into the dangerous drug, methamphetamine (meth) - will now be stocked by KERR DRUG chain of stores. "We are extremely pleased with KERR DRUG's decision to join the fight against methamphetamine abuse by stocking Nexafed," said Robert B. Jones, president and chief executive officer of Acura Pharmaceuticals. "We anticipated early interest in Nexafed from independent pharmacies but it is rewarding that forward-looking drug chains like KERR DRUG are stepping up to make a difference in the communities in which they operate." The Full Research Report on Acura Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/b2f1_ACUR]

Élan Corporation, PLC. Research Report

A unique cash flow dividend policy has been approved by the Board of Élan Corporation that'll enable its shareholders to benefit directly from the long term cash flow generated by Tysabri. The dividend program will be directly linked to Tysabri market performance calculated as a percentage of the Tysabri royalty paid to Élan from Biogen Idec as a result of the recently announced Tysabri restructuring. The initial percentage to be paid out directly to shareholders is 20 % of those royalties. The uncapped dividend cash payments give shareholders the right to enjoy unlimited participation in the upside from the Tysabri sales increase. The payments will be done in twice-yearly installments, with the first payment expected in the fourth quarter of 2013. The Full Research Report on Élan Corporation, PLC. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/294e_ELN]

Hospira, Inc. Research Report

Royce R. Bedward joins Hospira as its new corporate vice president, general counsel and secretary effective immediately. "Royce is an accomplished lawyer and integrity-driven business leader with more than 10 years of experience in the healthcare field and a proven track record of success at Hospira," said Mr. F. Michael Ball, Hospira CEO. "We look forward to Royce's many additional contributions, while thanking Brian for his continued service and counsel. Working together, I'm confident that their strong leadership abilities will help position Hospira for a stronger future of sustainable, long-term growth and drive greater value for our stakeholders. "Mr. Bedward will oversee the company's legal department, including litigation, benefits, labor and employment, intellectual property, governance, securities and transactional matters. Hospira, Inc. is the world's leading provider of injectable drugs and infusion technologies. Through its broad, integrated portfolio, Hospira is uniquely positioned to Advance Wellness by improving patient and caregiver safety while reducing healthcare costs. The company is headquartered in Lake Forest, Ill., and has approximately 16,000 employees. The full Research Report on Hospira, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/44b1_HSP]

Alkermes Plc. Research Report

It was a good third quarter for Alkermes as non-GAAP diluted EPS grew to $0.34 from $0.10, prompting improved financial expectations for its fiscal year 2013. "With results now spanning an entire year, the power of Alkermes Plc is becoming evident. Our strong financial performance was driven by our five key commercial products, which grew 33% year-over-year," commented James Frates, Chief Financial Officer of Alkermes. "Today, we are again improving our financial expectations for fiscal 2013, based on our robust operational performance across the business. We now expect Alkermes to generate between $135 million and $155 million in non-GAAP net income this fiscal year." Manufacturing and royalty revenues from the company's long-acting atypical antipsychotic franchise RISPERDAL, CONSTA, and INVEGA SUSTENNA/XEPLION amount to $52.5 million. Net sales, and royalty and manufacturing of its other products also contributed to the increase in revenue for the company. The Full Research Report on Alkermes Plc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/2f8e_ALKS]

Valeant Pharmaceuticals Intl Inc. Research Report

It was a healthy 2012 Q4 for Valeant Pharmaceuticals as the company posted good figures, thanks to organic growth. For Q4, total revenue amounted to $986 million, a 43% increase over the prior year with same store sales up by 7%. For the full year, the company enjoys a 44% increase in total revenue amounting to $3.55 billion versus 2011's $2.46 billion. The company's U.S. Dermatology business has shown solid growth, thanks to the sales performance of Zovirax, Retin-A Micro, Acanya, Carac and CeraVe. Valeant's other portfolio also delivered positive results, reflecting the diminishing year over year negative impact from generic competitors of Wellburtin XL, Ultram and Cardizem CD. The Full Research Report on Valeant Pharmaceuticals Intl Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/8d49_VRX]

Consider Investors Alliance

Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop - long before they become the next top news on major financial networks.

Contact: Patricia Byers
Email: press@investors-alliance.com
Main: +1-(408)-745-7826

SOURCE Investors-Alliance

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here